Everest Medicines' Licensing Partner NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study

Everest Medicines' Licensing Partner NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study

VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitor Topline Phase 2a data show VIS-101 provides rapid, robust and durable treatment responses in wet AMD VIS-101 demonstrated...

DPC Dash Ltd (1405.HK) to Announce Full Year 2025 Financial Results on March 25, 2026

DPC Dash Ltd (1405.HK) to Announce Full Year 2025 Financial Results on March 25, 2026

HONG KONG, March 13, 2026 /PRNewswire/ -- DPC Dash Ltd - Domino's Pizza China ("DPC Dash" or the "Company") (1405.HK), Domino's Pizza's exclusive master franchisee in the China Mainland, the Hong Kong Special Administrative Region of China, and the...

Sisram Medical to Announce 2025 Annual Results on Monday, March 23, 2026

Sisram Medical to Announce 2025 Annual Results on Monday, March 23, 2026

Earnings Conference Call to be Held on March 24, 2026 HONG KONG, March 12, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global wellness group...

Baozun to Announce Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results on March 25, 2026

Baozun to Announce Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results on March 25, 2026

SHANGHAI, March 11, 2026 /PRNewswire/ -- Baozun Inc. (Nasdaq: BZUN and HKEX: 9991) ("Baozun", the "Company" or the "Group"), a leading brand e-commerce solution provider and digital commerce enabler in China, today announced that it will release its...

Everest Medicines to Announce 2025 Full-Year Financial Results on March 26, 2026

Everest Medicines to Announce 2025 Full-Year Financial Results on March 26, 2026

SHANGHAI, March 10, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today...

Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Atopic Dermatitis

Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Atopic Dermatitis

CHENGDU, China, March 9, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) and Harbour BioMed (HKEX: 02142) today announced that the National Medical Products Administration (NMPA) of...

Health In Tech to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026

Health In Tech to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026

STUART, Fla., March 9, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT), an AI-enabled InsurTech platform company, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2025, following...

Gamehaus Holdings Inc. to Announce Unaudited Financial Results for the Second Quarter of Fiscal 2026 on March 23, 2026

Gamehaus Holdings Inc. to Announce Unaudited Financial Results for the Second Quarter of Fiscal 2026 on March 23, 2026

SHANGHAI, March 9, 2026 /PRNewswire/ -- Gamehaus Holdings Inc. ("Gamehaus" or the "Company") (Nasdaq: GMHS), a technology-driven mobile game publisher, today announced that it will release its unaudited financial results for the second quarter of...

Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis

Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 9, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and...

ZKH Group Limited to Announce Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 19, 2026

ZKH Group Limited to Announce Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 19, 2026

SHANGHAI, March 5, 2026 /PRNewswire/ -- ZKH Group Limited ("ZKH" or the "Company") (NYSE: ZKH), a leading maintenance, repair and operations ("MRO") procurement service platform in China, today announced that it will release its unaudited financial...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • menu
    menu